| Income Statement | 2025-09-30 | 2024-09-30 | ||
|---|---|---|---|---|
| Research and development | 9,156,474 | 11,906,601 | ||
| General and administrative | 18,532,843 | 18,249,402 | ||
| Stock-based compensation general and administrative | 10,836,291 | 11,839,678 | ||
| Total operating expenses | 38,525,608 | 41,995,681 | ||
| Operating loss | -38,525,608 | -41,995,681 | ||
| Gain (loss) on extinguishment of debt | - | 2,387,842 | ||
| Interest income | 110,081 | 758,000 | ||
| Interest expense | 267,782 | - | ||
| Total other income (expense), net | -157,701 | 3,145,842 | ||
| Loss before income taxes | -38,683,309 | -38,849,839 | ||
| Income tax expense | 1,056,960 | 576,000 | ||
| Net loss | -39,740,269 | -39,425,839 | ||
| Deemed dividend on warrant extension | - | 1,047,312 | ||
| Net loss attributable to non-controlling interest | -2,306,358 | -287,000 | ||
| Net loss applicable to common stockholders | -37,433,911 | -40,186,151 | ||
| Basic (in shares) | 11,065,225 | 6,726,999 | ||
| Diluted (in shares) | 11,065,225 | 6,726,999 | ||
| Net loss per share applicable to common stockholders - basic (in dollars per share) | -3.38 | -5.97 | ||
| Net loss per share applicable to common stockholders - diluted (in dollars per share) | -3.38 | -5.97 | ||
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)